Asli Gorek Dilektasli1, Janos Porszasz2, Richard Casaburi3, William W Stringer2, Surya P Bhatt4, Youngju Pak5, Harry B Rossiter6, George Washko7, Peter J Castaldi8, Raul San Jose Estepar7, James E Hansen2. 1. Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Department of Pulmonary Medicine, Faculty of Medicine, Uludağ University, Bursa, Turkey. 2. Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA. 3. Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA. Electronic address: casaburi@ucla.edu. 4. Division of Pulmonary, Allergy and Critical Care Medicine, UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL. 5. UCLA Clinical and Translational Science Institute, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA. 6. Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Faculty of Biological Sciences, University of Leeds, Leeds, England. 7. Brigham and Women's Hospital Clinics, Brigham and Women's Hospital, Boston, MA. 8. Channing Division of Network Medicine and Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA.
Abstract
BACKGROUND: In chronic obstructive pulmonary disease, both smaller and larger airways are affected. FEV1 mainly reflects large airways obstruction, while the later fraction of forced exhalation reflects reduction in terminal expiratory flow. In this study, the objective was to evaluate the relationship between spirometric ratios, including the ratio of forced expiratory volume in 3 and 6 seconds (FEV3/FEV6), and small airways measures and gas trapping at quantitative chest CT scanning, and clinical outcomes in the Genetic Epidemiology of COPD (COPDGene) cohort. METHODS: Seven thousand eight hundred fifty-three current and ex-smokers were evaluated for airflow obstruction by using recently defined linear iteratively derived equations of Hansen et al to determine lower limit of normal (LLN) equations for prebronchodilator FEV1/FVC, FEV1/FEV6, FEV3/FEV6, and FEV3/FVC. General linear and ordinal regression models were applied to the relationship between prebronchodilator spirometric and radiologic and clinical data. RESULTS: Of the 10,311 participants included in the COPDGene phase I study, participants with incomplete quantitative CT scanning or relevant spirometric data were excluded, resulting in 7,853 participants in the present study. Of 4,386 participants with FEV1/FVC greater than or equal to the LLN, 15.4% had abnormal FEV3/FEV6. Compared with normal FEV3/FEV6 and FEV1/FVC, abnormal FEV3/FEV6 was associated with significantly greater gas trapping; St. George's Respiratory Questionnaire score; modified Medical Research Council dyspnea score; and BMI, airflow obstruction, dyspnea, and exercise index and with shorter 6-min walking distance (all P < .0001) but not with CT scanning evidence of emphysema. CONCLUSIONS: Current and ex-smokers with prebronchodilator FEV3/FEV6 less than the LLN as the sole abnormality identifies a distinct population with evidence of small airways disease in quantitative CT scanning, impaired indexes of physical function and quality of life otherwise deemed normal by using the current spirometric definition.
BACKGROUND: In chronic obstructive pulmonary disease, both smaller and larger airways are affected. FEV1 mainly reflects large airways obstruction, while the later fraction of forced exhalation reflects reduction in terminal expiratory flow. In this study, the objective was to evaluate the relationship between spirometric ratios, including the ratio of forced expiratory volume in 3 and 6 seconds (FEV3/FEV6), and small airways measures and gas trapping at quantitative chest CT scanning, and clinical outcomes in the Genetic Epidemiology of COPD (COPDGene) cohort. METHODS: Seven thousand eight hundred fifty-three current and ex-smokers were evaluated for airflow obstruction by using recently defined linear iteratively derived equations of Hansen et al to determine lower limit of normal (LLN) equations for prebronchodilator FEV1/FVC, FEV1/FEV6, FEV3/FEV6, and FEV3/FVC. General linear and ordinal regression models were applied to the relationship between prebronchodilator spirometric and radiologic and clinical data. RESULTS: Of the 10,311 participants included in the COPDGene phase I study, participants with incomplete quantitative CT scanning or relevant spirometric data were excluded, resulting in 7,853 participants in the present study. Of 4,386 participants with FEV1/FVC greater than or equal to the LLN, 15.4% had abnormal FEV3/FEV6. Compared with normal FEV3/FEV6 and FEV1/FVC, abnormal FEV3/FEV6 was associated with significantly greater gas trapping; St. George's Respiratory Questionnaire score; modified Medical Research Council dyspnea score; and BMI, airflow obstruction, dyspnea, and exercise index and with shorter 6-min walking distance (all P < .0001) but not with CT scanning evidence of emphysema. CONCLUSIONS: Current and ex-smokers with prebronchodilator FEV3/FEV6 less than the LLN as the sole abnormality identifies a distinct population with evidence of small airways disease in quantitative CT scanning, impaired indexes of physical function and quality of life otherwise deemed normal by using the current spirometric definition.
Authors: M P Swanney; R L Jensen; D A Crichton; L E Beckert; L A Cardno; R O Crapo Journal: Am J Respir Crit Care Med Date: 2000-09 Impact factor: 21.405
Authors: H O Coxson; R M Rogers; K P Whittall; Y D'yachkova; P D Paré; F C Sciurba; J C Hogg Journal: Am J Respir Crit Care Med Date: 1999-03 Impact factor: 21.405
Authors: R A O'Donnell; C Peebles; J A Ward; A Daraker; G Angco; P Broberg; S Pierrou; J Lund; S T Holgate; D E Davies; D J Delany; S J Wilson; R Djukanovic Journal: Thorax Date: 2004-10 Impact factor: 9.139
Authors: Bartolome R Celli; Claudia G Cote; Jose M Marin; Ciro Casanova; Maria Montes de Oca; Reina A Mendez; Victor Pinto Plata; Howard J Cabral Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: William W Stringer; Janos Porszasz; Surya P Bhatt; Meredith C McCormack; Barry J Make; Richard Casaburi Journal: Chronic Obstr Pulm Dis Date: 2019-07-24
Authors: Nathan Yee; Daniela Markovic; Russell G Buhr; Spyridon Fortis; Mehrdad Arjomandi; David Couper; Wayne H Anderson; Robert Paine; Prescott G Woodruff; Meilan K Han; Fernando J Martinez; R Graham Barr; James M Wells; Victor E Ortega; Eric A Hoffman; Victor Kim; M Bradley Drummond; Russell P Bowler; Jeffrey L Curtis; Christopher B Cooper; Donald P Tashkin; Igor Z Barjaktarevic Journal: Chest Date: 2021-11-10 Impact factor: 10.262
Authors: Arthur F Gelb; Alfred Yamamoto; Eric K Verbeken; James C Hogg; Donald P Tashkin; Diem N T Tran; Roxanna M Moridzadeh; Christine Fraser; Mark J Schein; Marc Decramer; Eric F Glassy; Jay A Nadel Journal: Chronic Obstr Pulm Dis Date: 2021-01
Authors: Surya P Bhatt; Nirav R Bhakta; Carla G Wilson; Christopher B Cooper; Igor Barjaktarevic; Sandeep Bodduluri; Young-Il Kim; Michael Eberlein; Prescott G Woodruff; Frank C Sciurba; Peter J Castaldi; MeiLan K Han; Mark T Dransfield; Arie Nakhmani Journal: Sci Rep Date: 2018-11-30 Impact factor: 4.379
Authors: Brian L Graham; Irene Steenbruggen; Martin R Miller; Igor Z Barjaktarevic; Brendan G Cooper; Graham L Hall; Teal S Hallstrand; David A Kaminsky; Kevin McCarthy; Meredith C McCormack; Cristine E Oropez; Margaret Rosenfeld; Sanja Stanojevic; Maureen P Swanney; Bruce R Thompson Journal: Am J Respir Crit Care Med Date: 2019-10-15 Impact factor: 21.405
Authors: Nicole Probst-Hensch; Ayoung Jeong; Daiana Stolz; Marco Pons; Paola M Soccal; Robert Bettschart; Deborah Jarvis; John W Holloway; Florian Kronenberg; Medea Imboden; Christian Schindler; Gianfranco F Lovison Journal: Front Public Health Date: 2021-05-11